1.1Support after documented progression
Follow-up imaging measures tumor burden against a pretreatment baseline. Documented progression triggers review and selection of a nonviral treatment based on the tumor type.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Follow-up imaging measures tumor burden against a pretreatment baseline. Documented progression triggers review and selection of a nonviral treatment based on the tumor type.
An aqueous infusion delivers recombinant interleukin-2 as a protein. The protein binds interleukin-2 receptors on responsive immune cells and activates intracellular signaling.
One formulation contains purified tumor necrosis factor alpha, and the other contains purified interleukin-2. Separate containers allow each protein to be prepared and administered independently.
A buffered aqueous formulation carries recombinant interleukin-7. The protein binds the interleukin-7 receptor on responsive T cells and activates signaling that supports cell survival.
One formulation contains recombinant interleukin-7, and the other contains recombinant interleukin-2. Each protein engages its corresponding receptor, and separate administrations allow independent scheduling.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A clinical training simulator represents the mesothelin-directed cell therapy and the cytokine-vector therapy as separate mock orders. Trainees reconcile patient identifiers and record simulated handoffs for both orders. The simulator compares the entries with a scripted case and flags missing records or mismatched identifiers.
Mesothelin-coated alginate beads replace intact target cells in a receptor-binding demonstration. The beads sit in wells with fluorescently labeled soluble receptor fragments. A plate reader measures fluorescence retained after washing, and uncoated beads provide a background measurement.
A bead-based mesothelin binding assay runs in either 96-well or 384-well plates. Each layout assigns four wells to mesothelin-coated beads and four wells to uncoated controls per sample. The reader reports the difference between mean coated and uncoated fluorescence for each sample.
A hospital inventory system maintains separate records for the cell therapy and the cytokine-vector therapy. A shared treatment episode identifier links the records while each record retains its own lot identifier, storage location, and receipt timestamp. Staff scan each container at handoff, and the system compares the scanned identifier with the assigned record.
Image analysis software takes a digitized mesothelin-stained tissue section and a tumor region marked by a reviewer. The software segments cells, applies a configured membrane staining threshold, and calculates the fraction of positive cells in each marked region. It exports the counts and a segmentation overlay for review.
An event processor reads timestamped administration records for the cell therapy and the cytokine-vector therapy. It groups events by treatment episode and displays the recorded order and elapsed time between administrations. It sends missing timestamps and duplicate entries to a review queue.
The preceding administration ends before the cell infusion begins. The treatment record captures the end time of the preceding administration and the start time of the cell infusion.
patent.fyi, US 2026/0355268 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355268/, SHA-256 9d5f81fa854242358895039a411829319639e03f974786dd454c64cac6ad51c9